ON THIS PAGE
About Cancer Screening | About Multi-Cancer Detection (MCD) Tests
This study will look at the use of new technologies for cancer screening called Multi-Cancer Detection (MCD) tests. The goal is to learn more about these tests and find out if they can help people from all backgrounds to find cancer early when it may be easier to treat.
In this study, participants will be randomly assigned to one of three groups: the Intervention Group 1, the Intervention Group 2, or the Control Group. All participants will receive standard cancer screenings as part of their care.
- Arm 1 MCD test A (Intervention Group 1): Participants will receive the MCD test labeled 1.
- Arm 2 MCD test B (Intervention Group 2): Participants will receive the MCD test labeled 2.
- Arm 3 No MCD test (Control Group): Participants will not receive any MCD tests.
The study aims to:
- Learn if participants are okay with being randomly assigned to different groups.
- See if participants follow the testing and check-up schedules.
- Test if the planned steps for diagnosis work well.
- Make sure blood tests are done correctly and results come back on time.
- Find out what helps or makes it hard for different people to join, stay in, and follow the study rules.
What are ACCrual, Enrollment, and Screening Sites (ACCESS) Hubs?
The CSRN ACCESS Hubs are specialized centers contributing to the National Cancer Institute's cancer screening research effort. They bring together different healthcare teams, located in different part of the U.S., to find and sign up eligible participants for cancer screening studies. These hubs work with many hospitals and clinics to ensure a diverse group of people can join and stay informed throughout the course of the Vanguard Study. The goal is to discover new ways to detect cancer early and improve cancer screening.
The Vanguard Study will recruit people who do not currently have cancer and have not received a cancer diagnosis within the past 5 years. People with other health conditions can join as long as their conditions do not stop them from being able to complete the study steps.
We encourage you to contact a local study team to discuss your situation further. Find an ACCESS Hub in your region.
The Vanguard Study will look for people who do not currently have cancer and have not received a cancer diagnosis within the past 5 years.
People with high risks of cancer are not excluded from participating.
We encourage you to contact a local study team to discuss your situation further. Find an ACCESS Hub in your region.
The Vanguard Study does not recruite people who are currently taking part in another study that is testing a new cancer screening method or technology.
We encourage you to contact a local study team to discuss your situation further. Find an ACCESS Hub in your region.
In general, CSRN studies will try to include people who would benefit from cancer screening and those who are often left out of clinical trials. Each ACCESS Hub will ensure their enrolled participants reflect the diversity of their communities.
The Vanguard Study is looking for people who do not currently have cancer and have not received a cancer diagnosis within the past 5 years.
We encourage you to contact a local study team to discuss your situation further. Find an ACCESS Hub in your region.
- Ages 45-75 years old.
- Do not currently have a cancer diagnosis and have not received a cancer diagnosis within the past 5 years.
- Willing to give blood samples at enrollment and after 1 year.
- Understand and be able to complete study documents in English, Spanish, or Arabic.
- Not currently breastfeeding, pregnant, or planning to become pregnant within the next year.
- Not currently participating in another study testing a new cancer screening method or technology.
We encourage you to contact a local study team to discuss your situation further. Find an ACCESS Hub in your region.